TIMP-1 increases expression and phosphorylation of proteins associated with drug resistance in breast cancer cells

Journal of Proteome Research

Volumn 12, Issue 9, 2013, Pages 4136-4151

  Hekmat, Omid ^c   Munk, Stephanie ^c   Fogh, Louise ^a,b   Yadav, Rachita ^b,d   Francavilla, Chiara ^c   Horn, Heiko ^c   Würtz, Sidse Ørnbjerg ^a,b   Schrohl, Anne Sofie ^a,b   Damsgaard, Britt ^a,b   Rømer, Maria Unni ^a,b   Belling, Kirstine C ^a,b   Jensen, Niels Frank ^a,b   Gromova, Irina ^e   Bekker Jensen, Dorte B ^c   Moreira, José M ^a,b   Jensen, Lars J ^c   Gupta, Ramneek ^b,d   Lademann, Ulrik ^a,b   Brünner, Nils ^a,b   Olsen, Jesper V ^c,d   Stenvang, Jan ^a,b   more..

^a UNIVERSITY OF COPENHAGEN   (Denmark)

^b UNIVERSITY OF COPENHAGEN   (Denmark)

^c University of Copenhagen   (Denmark)

^d TECHNICAL UNIVERSITY OF DENMARK   (Denmark)

^e DANISH CANCER SOCIETY RESEARCH CENTER   (Denmark)

Author keywords

breast cancer; phosphoproteomics; quantitative mass spectrometry; resistance to chemotherapy; SILAC; tissue inhibitor of metalloproteinase 1; topoisomerase; two dimensional PAGE

Indexed keywords

ATM PROTEIN; CASEIN KINASE; CASEIN KINASE IIALPHA; CD63 ANTIGEN; CISPLATIN; CLUSTERIN; CYCLIN DEPENDENT KINASE 1; DNA TOPOISOMERASE; DNA TOPOISOMERASE 2ALPHA; DNA TOPOISOMERASE 2BETA; DNA TOPOISOMERASE INHIBITOR; EPIRUBICIN; ETOPOSIDE; FIRTECAN; HERMES ANTIGEN; ISOMERASE; MAMMALIAN TARGET OF RAPAMYCIN; POLO LIKE KINASE 1; PROPIONIC ACID DERIVATIVE; PROTEIN; STABLE ISOTOPE; TISSUE INHIBITOR OF METALLOPROTEINASE 1; TRANSCRIPTION FACTOR FRA 2; TRANSCRIPTION FACTOR JUNB; UNCLASSIFIED DRUG; XK 469;

ANIMAL CELL; APOPTOSIS; ARTICLE; BREAST CANCER; CANCER CELL CULTURE; CANCER CHEMOTHERAPY; CELL CYCLE; CELL STRAIN MCF 7; COLORECTAL CANCER; CONTROLLED STUDY; DNA REPAIR; DRUG SENSITIVITY; DRUG TARGETING; DRUG TRANSPORT; FIBROSARCOMA; GENETIC ALGORITHM; HUMAN; HUMAN CELL; IC 50; INTRACELLULAR SIGNALING; ISOTOPE LABELING; NONHUMAN; PHENOTYPE; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; PROTEOMICS; TANDEM MASS SPECTROMETRY; UPREGULATION; WILD TYPE;

AMINO ACID SEQUENCE; ANTINEOPLASTIC AGENTS; BREAST NEOPLASMS; CELL SURVIVAL; CISPLATIN; CONSENSUS SEQUENCE; DNA TOPOISOMERASES, TYPE I; DNA TOPOISOMERASES, TYPE II; DNA-BINDING PROTEINS; DRUG RESISTANCE, NEOPLASM; FEMALE; GENE EXPRESSION; HUMANS; MCF-7 CELLS; MOLECULAR SEQUENCE DATA; PHOSPHORYLATION; PROTEIN INTERACTION MAPS; PROTEIN PROCESSING, POST-TRANSLATIONAL; PROTEOME; TISSUE INHIBITOR OF METALLOPROTEINASE-1; TOPOISOMERASE INHIBITORS;

EID: 84883774480     PISSN: 15353893     EISSN: 15353907     Source Type: Journal    
DOI: 10.1021/pr400457u     Document Type: Article

References (72)

1. Early Breast Cancer Trialists' Collaborative Group (EBCTCG) Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: An overview of the randomised trials Lancet 2005, 365 (9472) 1687-1717
2. Peto, R.; Davies, C.; Godwin, J.; Gray, R.; Pan, H. C.; Clarke, M.; Cutter, D.; Darby, S.; McGale, P.; Taylor, C.; Wang, Y. C.; Bergh, J.; Di, L. A.; Albain, K.; Swain, S.; Piccart, M.; Pritchard, K. Comparisons between different polychemotherapy regimens for early breast cancer: meta-analyses of long-term outcome among 100,000 women in 123 randomised trials Lancet 2012, 379 (9814) 432-444
3. Egeblad, M.; Werb, Z. New functions for the matrix metalloproteinases in cancer progression Nat. Rev. Cancer 2002, 2 (3) 161-174
4. Stetler-Stevenson, W. G. Tissue inhibitors of metalloproteinases in cell signaling: metalloproteinase-independent biological activities Sci. Signaling 2008, 1 (27) re6
5. Wurtz, S. O.; Schrohl, A. S.; Sorensen, N. M.; Lademann, U.; Christensen, I. J.; Mouridsen, H.; Brunner, N. Tissue inhibitor of metalloproteinases-1 in breast cancer Endocr.-Relat. Cancer 2005, 12 (2) 215-227
6. Airola, K.; Karonen, T.; Vaalamo, M.; Lehti, K.; Lohi, J.; Kariniemi, A. L.; Keski-Oja, J.; Saarialho-Kere, U. K. Expression of collagenases-1 and -3 and their inhibitors TIMP-1 and -3 correlates with the level of invasion in malignant melanomas Br. J. Cancer 1999, 80 (5-6) 733-743
7. Liu, X. W.; Bernardo, M. M.; Fridman, R.; Kim, H. R. Tissue inhibitor of metalloproteinase-1 protects human breast epithelial cells against intrinsic apoptotic cell death via the focal adhesion kinase/phosphatidylinositol 3-kinase and MAPK signaling pathway J. Biol. Chem. 2003, 278 (41) 40364-40372
8. Liu, X. W.; Taube, M. E.; Jung, K. K.; Dong, Z.; Lee, Y. J.; Roshy, S.; Sloane, B. F.; Fridman, R.; Kim, H. R. Tissue inhibitor of metalloproteinase-1 protects human breast epithelial cells from extrinsic cell death: A potential oncogenic activity of tissue inhibitor of metalloproteinase-1 Cancer Res. 2005, 65 (3) 898-906
9. Jung, K. K.; Liu, X. W.; Chirco, R.; Fridman, R.; Kim, H. R. Identification of CD63 as a tissue inhibitor of metalloproteinase-1 interacting cell surface protein EMBO J. 2006, 25 (17) 3934-3942
10. Wang, T.; Lv, J. H.; Zhang, X. F.; Li, C. J.; Han, X.; Sun, Y. J. Tissue inhibitor of metalloproteinase-1 protects MCF-7 breast cancer cells from paclitaxel-induced apoptosis by decreasing the stability of cyclin B1 Int. J. Cancer 2010, 126 (2) 362-370
11. Fu, Z. Y.; Lv, J. H.; Ma, C. Y.; Yang, D. P.; Wang, T. Tissue inhibitor of metalloproteinase-1 decreased chemosensitivity of MDA-435 breast cancer cells to chemotherapeutic drugs through the PI3K/AKT/NF-small ka, CyrillicB pathway Biomed. Pharmacother. 2011, 65 (3) 163-167
12. Willemoe, G. L.; Hertel, P. B.; Bartels, A.; Jensen, M. B.; Balslev, E.; Rasmussen, B. B.; Mouridsen, H.; Ejlertsen, B.; Brunner, N. Lack of TIMP-1 tumour cell immunoreactivity predicts effect of adjuvant anthracycline-based chemotherapy in patients (n = 647) with primary breast cancer. A Danish Breast Cancer Cooperative Group Study Eur. J. Cancer 2009, 45 (14) 2528-2536
13. Ejlertsen, B.; Jensen, M. B.; Nielsen, K. V.; Balslev, E.; Rasmussen, B. B.; Willemoe, G. L.; Hertel, P. B.; Knoop, A. S.; Mouridsen, H. T.; Brunner, N. HER2, TOP2A, and TIMP-1 and responsiveness to adjuvant anthracycline-containing chemotherapy in high-risk breast cancer patients J. Clin. Oncol. 2010, 28 (6) 984-990
14. Sorensen, N. M.; Bystrom, P.; Christensen, I. J.; Berglund, A.; Nielsen, H. J.; Brunner, N.; Glimelius, B. TIMP-1 is significantly associated with objective response and survival in metastatic colorectal cancer patients receiving combination of irinotecan, 5-fluorouracil, and folinic acid Clin. Cancer Res. 2007, 13 (14) 4117-4122
15. Frederiksen, C.; Qvortrup, C.; Christensen, I. J.; Glimelius, B.; Berglund, A.; Jensen, B. V.; Nielsen, S. E.; Keldsen, N.; Nielsen, H. J.; Brunner, N.; Pfeiffer, P. Plasma TIMP-1 levels and treatment outcome in patients treated with XELOX for metastatic colorectal cancer Ann. Oncol. 2011, 22 (2) 369-375
16. Schrohl, A. S.; Christensen, I. J.; Pedersen, A. N.; Jensen, V.; Mouridsen, H.; Murphy, G.; Foekens, J. A.; Brunner, N.; Holten-Andersen, M. N. Tumor tissue concentrations of the proteinase inhibitors tissue inhibitor of metalloproteinases-1 (TIMP-1) and plasminogen activator inhibitor type 1 (PAI-1) are complementary in determining prognosis in primary breast cancer Mol. Cell. Proteomics 2003, 2 (3) 164-172
17. Wurtz, S. O.; Christensen, I. J.; Schrohl, A. S.; Mouridsen, H.; Lademann, U.; Jensen, V.; Brunner, N. Measurement of the uncomplexed fraction of tissue inhibitor of metalloproteinases-1 in the prognostic evaluation of primary breast cancer patients Mol. Cell. Proteomics 2005, 4 (4) 483-491
18. Birgisson, H.; Nielsen, H. J.; Christensen, I. J.; Glimelius, B.; Brunner, N. Preoperative plasma TIMP-1 is an independent prognostic indicator in patients with primary colorectal cancer: A prospective validation study Eur. J. Cancer 2010, 46 (18) 3323-3331
19. Bigelow, R. L.; Williams, B. J.; Carroll, J. L.; Daves, L. K.; Cardelli, J. A. TIMP-1 overexpression promotes tumorigenesis of MDA-MB-231 breast cancer cells and alters expression of a subset of cancer promoting genes in vivo distinct from those observed in vitro Breast Cancer Res. Treat. 2009, 117 (1) 31-44
20. Stilley, J. A.; Sharpe-Timms, K. L. TIMP1 contributes to ovarian anomalies in both an MMP-dependent and -independent manner in a rat model Biol. Reprod. 2012, 86 (2) 47
21. Egea, V.; Zahler, S.; Rieth, N.; Neth, P.; Popp, T.; Kehe, K.; Jochum, M.; Ries, C. Tissue inhibitor of metalloproteinase-1 (TIMP-1) regulates mesenchymal stem cells through let-7f microRNA and Wnt/beta-catenin signaling Proc. Natl. Acad. Sci. U.S.A. 2012, 109 (6) E309-E316
22. Schrohl, A. S.; Meijer-van Gelder, M. E.; Holten-Andersen, M. N.; Christensen, I. J.; Look, M. P.; Mouridsen, H. T.; Brunner, N.; Foekens, J. A. Primary tumor levels of tissue inhibitor of metalloproteinases-1 are predictive of resistance to chemotherapy in patients with metastatic breast cancer Clin. Cancer Res. 2006, 12 (23) 7054-7058
23. Sorensen, N. M.; Schrohl, A. S.; Jensen, V.; Christensen, I. J.; Nielsen, H. J.; Brunner, N. Comparative studies of tissue inhibitor of metalloproteinases-1 in plasma, serum and tumour tissue extracts from patients with primary colorectal cancer Scand. J. Gastroenterol. 2008, 43 (2) 186-191
24. Cox, J.; Mann, M. Quantitative, high-resolution proteomics for data-driven systems biology Annu. Rev. Biochem. 2011, 80, 273-299
25. Ong, S. E.; Blagoev, B.; Kratchmarova, I.; Kristensen, D. B.; Steen, H.; Pandey, A.; Mann, M. Stable isotope labeling by amino acids in cell culture, SILAC, as a simple and accurate approach to expression proteomics Mol. Cell. Proteomics 2002, 1 (5) 376-386
26. Jaattela, M.; Benedict, M.; Tewari, M.; Shayman, J. A.; Dixit, V. M. Bcl-x and Bcl-2 inhibit TNF and Fas-induced apoptosis and activation of phospholipase A2 in breast carcinoma cells Oncogene 1995, 10 (12) 2297-2305
27. Cox, J.; Matic, I.; Hilger, M.; Nagaraj, N.; Selbach, M.; Olsen, J. V.; Mann, M. A practical guide to the MaxQuant computational platform for SILAC-based quantitative proteomics Nat. Protoc. 2009, 4 (5) 698-705
28. Davidsen, M. L.; Wurtz, S. O.; Romer, M. U.; Sorensen, N. M.; Johansen, S. K.; Christensen, I. J.; Larsen, J. K.; Offenberg, H.; Brunner, N.; Lademann, U. TIMP-1 gene deficiency increases tumour cell sensitivity to chemotherapy-induced apoptosis Br. J. Cancer 2006, 95 (8) 1114-1120
29. Macek, B.; Mann, M.; Olsen, J. V. Global and site-specific quantitative phosphoproteomics: principles and applications Annu. Rev. Pharmacol. Toxicol. 2009, 49, 199-221
30. Olsen, J. V.; Macek, B. High accuracy mass spectrometry in large-scale analysis of protein phosphorylation Methods Mol. Biol. 2009, 492, 131-142
31. Olsen, J. V.; Schwartz, J. C.; Griep-Raming, J.; Nielsen, M. L.; Damoc, E.; Denisov, E.; Lange, O.; Remes, P.; Taylor, D.; Splendore, M.; Wouters, E. R.; Senko, M.; Makarov, A.; Mann, M.; Horning, S. A dual pressure linear ion trap Orbitrap instrument with very high sequencing speed Mol. Cell. Proteomics 2009, 8 (12) 2759-2769
32. Olsen, J. V.; de Godoy, L. M.; Li, G.; Macek, B.; Mortensen, P.; Pesch, R.; Makarov, A.; Lange, O.; Horning, S.; Mann, M. Parts per million mass accuracy on an Orbitrap mass spectrometer via lock mass injection into a C-trap Mol. Cell. Proteomics 2005, 4 (12) 2010-2021
33. Olsen, J. V.; Macek, B.; Lange, O.; Makarov, A.; Horning, S.; Mann, M. Higher-energy C-trap dissociation for peptide modification analysis Nat. Methods 2007, 4 (9) 709-712
34. Cox, J.; Mann, M. MaxQuant enables high peptide identification rates, individualized ppb-range mass accuracies and proteome-wide protein quantification Nat. Biotechnol. 2008, 26 (12) 1367-1372
35. Olsen, J. V.; Blagoev, B.; Gnad, F.; Macek, B.; Kumar, C.; Mortensen, P.; Mann, M. Global, in vivo, and site-specific phosphorylation dynamics in signaling networks Cell 2006, 127 (3) 635-648
36. Szklarczyk, D.; Franceschini, A.; Kuhn, M.; Simonovic, M.; Roth, A.; Minguez, P.; Doerks, T.; Stark, M.; Muller, J.; Bork, P.; Jensen, L. J.; von, M. C. The STRING database in 2011: functional interaction networks of proteins, globally integrated and scored Nucleic Acids Res. 2011, 39 (Database issue) D561-D568
37. von, M. C.; Jensen, L. J.; Snel, B.; Hooper, S. D.; Krupp, M.; Foglierini, M.; Jouffre, N.; Huynen, M. A.; Bork, P. STRING: known and predicted protein-protein associations, integrated and transferred across organisms Nucleic Acids Res. 2005, 33 (Database issue) D433-D437
38. Taboureau, O.; Nielsen, S. K.; Audouze, K.; Weinhold, N.; Edsgard, D.; Roque, F. S.; Kouskoumvekaki, I.; Bora, A.; Curpan, R.; Jensen, T. S.; Brunak, S.; Oprea, T. I. ChemProt: A disease chemical biology database Nucleic Acids Res. 2011, 39 (Database issue) D367-D372
39. Knox, C.; Law, V.; Jewison, T.; Liu, P.; Ly, S.; Frolkis, A.; Pon, A.; Banco, K.; Mak, C.; Neveu, V.; Djoumbou, Y.; Eisner, R.; Guo, A. C.; Wishart, D. S. DrugBank 3.0: A comprehensive resource for 'omics' research on drugs Nucleic Acids Res. 2011, 39 (Database issue) D1035-D1041
40. Smoot, M. E.; Ono, K.; Ruscheinski, J.; Wang, P. L.; Ideker, T. Cytoscape 2.8: new features for data integration and network visualization Bioinformatics 2011, 27 (3) 431-432
41. Warsow, G.; Greber, B.; Falk, S. S.; Harder, C.; Siatkowski, M.; Schordan, S.; Som, A.; Endlich, N.; Scholer, H.; Repsilber, D.; Endlich, K.; Fuellen, G. ExprEssence - revealing the essence of differential experimental data in the context of an interaction/regulation net-work BMC Syst. Biol. 2010, 4, 164
42. Colaert, N.; Helsens, K.; Martens, L.; Vandekerckhove, J.; Gevaert, K. Improved visualization of protein consensus sequences by iceLogo Nat. Methods 2009, 6 (11) 786-787
43. Linding, R.; Jensen, L. J.; Ostheimer, G. J.; van Vugt, M. A.; Jorgensen, C.; Miron, I. M.; Diella, F.; Colwill, K.; Taylor, L.; Elder, K.; Metalnikov, P.; Nguyen, V.; Pasculescu, A.; Jin, J.; Park, J. G.; Samson, L. D.; Woodgett, J. R.; Russell, R. B.; Bork, P.; Yaffe, M. B.; Pawson, T. Systematic discovery of in vivo phosphorylation networks Cell 2007, 129 (7) 1415-1426
44. Miller, M. L.; Jensen, L. J.; Diella, F.; Jorgensen, C.; Tinti, M.; Li, L.; Hsiung, M.; Parker, S. A.; Bordeaux, J.; Sicheritz-Ponten, T.; Olhovsky, M.; Pasculescu, A.; Alexander, J.; Knapp, S.; Blom, N.; Bork, P.; Li, S.; Cesareni, G.; Pawson, T.; Turk, B. E.; Yaffe, M. B.; Brunak, S.; Linding, R. Linear motif atlas for phosphorylation-dependent signaling Sci. Signaling 2008, 1 (35) ra2
45. Moller, S. N.; Dowell, B. L.; Stewart, K. D.; Jensen, V.; Larsen, L.; Lademann, U.; Murphy, G.; Nielsen, H. J.; Brunner, N.; Davis, G. J. Establishment and characterization of 7 new monoclonal antibodies to tissue inhibitor of metalloproteinases-1 Tumour Biol. 2005, 26 (2) 71-80
46. Holten-Andersen, M. N.; Murphy, G.; Nielsen, H. J.; Pedersen, A. N.; Christensen, I. J.; Hoyer-Hansen, G.; Brunner, N.; Stephens, R. W. Quantitation of TIMP-1 in plasma of healthy blood donors and patients with advanced cancer Br. J. Cancer 1999, 80 (3-4) 495-503
47. Cabezon, T.; Gromova, I.; Gromov, P.; Serizawa, R.; Timmermans, W., V; Kroman, N.; Celis, J. E.; Moreira, J. M. Proteomic Profiling of Triple-negative Breast Carcinomas in Combination With a Three-tier Orthogonal Technology Approach Identifies Mage-A4 as Potential Therapeutic Target in Estrogen Receptor Negative Breast Cancer Mol. Cell. Proteomics 2013, 12 (2) 381-394
48. Pines, A.; Kelstrup, C. D.; Vrouwe, M. G.; Puigvert, J. C.; Typas, D.; Misovic, B.; de, G. A.; von, S. L.; van de Water, B.; Danen, E. H.; Vrieling, H.; Mullenders, L. H.; Olsen, J. V. Global phosphoproteome profiling reveals unanticipated networks responsive to cisplatin treatment of embryonic stem cells Mol. Cell. Biol. 2011, 31 (24) 4964-4977
49. de Godoy, L. M.; Olsen, J. V.; Cox, J.; Nielsen, M. L.; Hubner, N. C.; Frohlich, F.; Walther, T. C.; Mann, M. Comprehensive mass-spectrometry-based proteome quantification of haploid versus diploid yeast Nature 2008, 455 (7217) 1251-1254
50. Selbach, M.; Schwanhausser, B.; Thierfelder, N.; Fang, Z.; Khanin, R.; Rajewsky, N. Widespread changes in protein synthesis induced by microRNAs Nature 2008, 455 (7209) 58-63
51. Lambert, E.; Bridoux, L.; Devy, J.; Dasse, E.; Sowa, M. L.; Duca, L.; Hornebeck, W.; Martiny, L.; Petitfrere-Charpentier, E. TIMP-1 binding to proMMP-9/CD44 complex localized at the cell surface promotes erythroid cell survival Int. J. Biochem. Cell Biol. 2009, 41 (5) 1102-1115
52. Lourda, M.; Trougakos, I. P.; Gonos, E. S. Development of resistance to chemotherapeutic drugs in human osteosarcoma cell lines largely depends on up-regulation of Clusterin/Apolipoprotein J Int. J. Cancer 2007, 120 (3) 611-622
53. Mizutani, K.; Matsumoto, K.; Hasegawa, N.; Deguchi, T.; Nozawa, Y. Expression of clusterin, XIAP and survivin, and their changes by camptothecin (CPT) treatment in CPT-resistant PC-3 and CPT-sensitive LNCaP cells Exp. Oncol. 2006, 28 (3) 209-215
54. Wang, Y. H.; Huang, M. L. Organogenesis and tumorigenesis: insight from the JAK/STAT pathway in the Drosophila eye Dev. Dyn. 2010, 239 (10) 2522-2533
55. Bucher, N.; Britten, C. D. G2 checkpoint abrogation and checkpoint kinase-1 targeting in the treatment of cancer Br. J. Cancer 2008, 98 (3) 523-528
56. Gaur, S.; Chen, L.; Yang, L.; Wu, X.; Un, F.; Yen, Y. Inhibitors of mTOR overcome drug resistance from topoisomerase II inhibitors in solid tumors Cancer Lett. 2011, 311 (1) 20-28
57. Ubersax, J. A.; Ferrell, J. E., Jr. Mechanisms of specificity in protein phosphorylation Nat. Rev. Mol. Cell Biol. 2007, 8 (7) 530-541
58. Alborzinia, H.; Can, S.; Holenya, P.; Scholl, C.; Lederer, E.; Kitanovic, I.; Wolfl, S. Real-time monitoring of cisplatin-induced cell death PLoS One 2011, 6 (5) e19714
59. Li, G.; Fridman, R.; Kim, H. R. Tissue inhibitor of metalloproteinase-1 inhibits apoptosis of human breast epithelial cells Cancer Res. 1999, 59 (24) 6267-6275
60. Ackerman, P.; Glover, C. V.; Osheroff, N. Phosphorylation of DNA topoisomerase II by casein kinase II: modulation of eukaryotic topoisomerase II activity in vitro Proc. Natl. Acad. Sci. U.S.A. 1985, 82 (10) 3164-3168
61. Bandyopadhyay, K.; Gjerset, R. A. Protein kinase CK2 is a central regulator of topoisomerase I hyperphosphorylation and camptothecin sensitivity in cancer cell lines Biochemistry 2011, 50 (5) 704-714
62. Hackbarth, J. S.; Galvez-Peralta, M.; Dai, N. T.; Loegering, D. A.; Peterson, K. L.; Meng, X. W.; Karnitz, L. M.; Kaufmann, S. H. Mitotic phosphorylation stimulates DNA relaxation activity of human topoisomerase I J. Biol. Chem. 2008, 283 (24) 16711-16722
63. Ritter, L. M.; Garfield, S. H.; Thorgeirsson, U. P. Tissue inhibitor of metalloproteinases-1 (TIMP-1) binds to the cell surface and translocates to the nucleus of human MCF-7 breast carcinoma cells Biochem. Biophys. Res. Commun. 1999, 257 (2) 494-499
64. Baselga, J. Targeting the phosphoinositide-3 (PI3) kinase pathway in breast cancer Oncologist 2011, 16 (Suppl 1) 12-19
65. McCubrey, J. A.; Steelman, L. S.; Chappell, W. H.; Abrams, S. L.; Wong, E. W.; Chang, F.; Lehmann, B.; Terrian, D. M.; Milella, M.; Tafuri, A.; Stivala, F.; Libra, M.; Basecke, J.; Evangelisti, C.; Martelli, A. M.; Franklin, R. A. Roles of the Raf/MEK/ERK pathway in cell growth, malignant transformation and drug resistance Biochim. Biophys. Acta 2007, 1773 (8) 1263-1284
66. Hayakawa, T.; Yamashita, K.; Tanzawa, K.; Uchijima, E.; Iwata, K. Growth-promoting activity of tissue inhibitor of metalloproteinases-1 (TIMP-1) for a wide range of cells. A possible new growth factor in serum FEBS Lett. 1992, 298 (1) 29-32
67. Luparello, C.; Avanzato, G.; Carella, C.; Pucci-Minafra, I. Tissue inhibitor of metalloprotease (TIMP)-1 and proliferative behaviour of clonal breast cancer cells Breast Cancer Res. Treat. 1999, 54 (3) 235-244
68. Peng, L.; Yanjiao, M.; Ai-guo, W.; Pengtao, G.; Jianhua, L.; Ju, Y.; Hongsheng, O.; Xichen, Z. A fine balance between CCNL1 and TIMP1 contributes to the development of breast cancer cells Biochem. Biophys. Res. Commun. 2011, 409 (2) 344-349
69. Bjerre, C.; Knoop, A.; Bjerre, K.; Larsen, M. S.; Henriksen, K. L.; Lyng, M. B.; Ditzel, H. J.; Rasmussen, B. B.; Brunner, N.; Ejlertsen, B.; Laenkholm, A. V. Association of tissue inhibitor of metalloproteinases-1 and Ki67 in estrogen receptor positive breast cancer Acta Oncol. 2013, 52 (1) 82-90
70. Li, H.; Wang, Y.; Liu, X. Plk1-dependent phosphorylation regulates functions of DNA topoisomerase IIalpha in cell cycle progression J. Biol. Chem. 2008, 283 (10) 6209-6221
71. Nakajima, H.; Toyoshima-Morimoto, F.; Taniguchi, E.; Nishida, E. Identification of a consensus motif for Plk (Polo-like kinase) phosphorylation reveals Myt1 as a Plk1 substrate J. Biol. Chem. 2003, 278 (28) 25277-25280
72. Toyoshima-Morimoto, F.; Taniguchi, E.; Shinya, N.; Iwamatsu, A.; Nishida, E. Polo-like kinase 1 phosphorylates cyclin B1 and targets it to the nucleus during prophase Nature 2001, 410 (6825) 215-220